KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Return on Capital Employed (2016 - 2026)

TherapeuticsMD filings provide 15 years of Return on Capital Employed readings, the most recent being 11.72% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 562.0% to 11.72% in Q1 2026 year-over-year; TTM through Mar 2026 was 11.72%, a 562.0% increase, with the full-year FY2025 number at 13.12%, up 390.0% from a year prior.
  • Return on Capital Employed hit 11.72% in Q1 2026 for TherapeuticsMD, up from 13.15% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 446.57% in Q2 2022 to a low of 21.28% in Q4 2023.
  • Median Return on Capital Employed over the past 5 years was 11.16% (2025), compared with a mean of 50.06%.
  • Biggest five-year swings in Return on Capital Employed: skyrocketed 52966bps in 2022 and later crashed -37849bps in 2023.
  • TherapeuticsMD's Return on Capital Employed stood at 1.82% in 2022, then crashed by -1268bps to 21.28% in 2023, then rose by 21bps to 16.8% in 2024, then grew by 22bps to 13.15% in 2025, then grew by 11bps to 11.72% in 2026.
  • The last three reported values for Return on Capital Employed were 11.72% (Q1 2026), 13.15% (Q4 2025), and 10.37% (Q3 2025) per Business Quant data.